Swiss Federal Institute of Aquatic Science and Technology

Nature Medicine Publication Highlights Potential for ONWARD® ARC Therapy™ to Improve Mobility After Parkinson’s Disease

Retrieved on: 
Monday, November 6, 2023
Euronext, The Michael J. Fox Foundation, Medical research, Swiss Federal Institute of Aquatic Science and Technology, MJFF, Teaching hospital, Clinical research, SCI, Research, INSERM, CHUV, Rehabilitation, Parkinson's disease, EPFL, Spinal cord, Swiss, ARC, Movement, Patient, Pharmaceutical industry, Medical device, Electric light, Nature Medicine

The study participant described in the Nature Medicine publication has been living with Parkinson’s disease for nearly three decades.

Key Points: 
  • The study participant described in the Nature Medicine publication has been living with Parkinson’s disease for nearly three decades.
  • The team collaborated with Dr. Erwan Bezard, a renowned neuroscientist from France’s National Institute of Health and Medical Research (INSERM).
  • Fox Foundation for Parkinson’s Research (MJFF) to implant the ARC-IM System and investigate the effect of ARC Therapy in six additional participants with Parkinson’s disease.
  • This study will assist ONWARD in determining whether to conduct additional clinical trials and potentially commercialize ARC Therapy in the future for those living with Parkinson’s disease.

Global Virus Network’s Top Virologists Partner with Monaco to Advance Pandemic Preparedness Across EU Countries

Retrieved on: 
Friday, October 20, 2023
Global Virus Network, Big data, Artificial intelligence, Disease, Risk, Partnership, Public, AI, Citizen science, Hospital, Infection, Swiss Federal Institute of Technology, Medical research, SARS-CoV-2, Vaccine, HIV, CSM, University, United States National Library of Medicine, WHO, Duke–NUS Medical School, Data collection, Research, Prince, Politics, COVID, World Health Organization, Travel, Privacy, Rega Institute for Medical Research, European Bioinformatics Institute, Climate change, National library, Swiss Federal Institute of Aquatic Science and Technology, GVN, Virus, Genomics, Casino, Pharmaceutical industry, Medical device

Prince Albert II of Monaco, among other dignitaries including from the World Health Organization (WHO) and the GVN.

Key Points: 
  • Prince Albert II of Monaco, among other dignitaries including from the World Health Organization (WHO) and the GVN.
  • Prince Albert II of Monaco said, “I am delighted to support and attend this symposium to improve pandemic preparedness here in Monaco and abroad.
  • We have a duty to remain vigilant, strengthen global governance, and strengthen infrastructure and healthcare systems.
  • Studies showed that phone apps tracking COVID cases and notifying those with exposure, significantly impacted hospitalization and death rates.

Safer and more Effective Brain Interfaces: First in Human Brain Recordings Achieved by Neurosoft Bioelectronics

Retrieved on: 
Tuesday, October 3, 2023
Oncology, Health, Medical Devices, Neurology, Health Technology, Clinical Trials, Biotechnology, Epilepsy, Swiss, Swiss Federal Institute of Technology, Digital Writing and Research Lab, Tinnitus, Deafness, Auditory cortex, Brain, Multimedia, Research, Biomarker, Trial of the century, Paralysis, DSM-IV codes, Wyss Center for Bio and Neuroengineering, Electrode, Patient, Traumatic brain injury, Memorial Hermann Health System, Hematoma, EPFL, FDA, Swiss Federal Institute of Aquatic Science and Technology, Safety, Hippocampus, Medical imaging, Medical device, Nursing

Two epileptic patients and one brain tumour patient have undergone a successful surgery, while detailed recordings were obtained in parallel from the surface of the brain.

Key Points: 
  • Two epileptic patients and one brain tumour patient have undergone a successful surgery, while detailed recordings were obtained in parallel from the surface of the brain.
  • Furthermore, the application of Neurosoft Bioelectronics’ electrodes presents the possibility of uncovering supplementary biomarkers which could significantly help in providing more effective and safer treatments of brain disorders for future patients.
  • Amidst these challenges, Neurosoft Bioelectronics' soft and elastic electrodes present themselves as a promising alternative to existing invasive solutions.
  • The Neurosoft Bioelectronics team has also been studying how these electrodes could address indications like severe tinnitus.

Student Entrepreneurs from Yale University Win Prestigious $1 Million 2023 Hult Prize

Retrieved on: 
Saturday, September 23, 2023
Luxury, Fund Raising, Professional Services, Foundation, Philanthropy, Consumer, Collegiate, Textiles, Fashion, University, Manufacturing, Sustainability, Retail, Start-Up, Education, Environment, Entrepreneur, Prize, Learning, Yale University, Hult Prize, Recycling, United Nations, Optimism, National Taiwan University, Cranfield University, Sustainable Development Goals, Hult International Business School, ETH Zurich, Object, Student, Entrepreneurship, Alexandria University, Art, Seumas McNally Grand Prize, United, UN, Social change, Pleasure, City, EF Education First, Growth, Paris Fashion Week, Food, Hult, Swiss Federal Institute of Aquatic Science and Technology, Tourism, Pharmaceutical industry, Video game, Final

Just days before the start of Paris Fashion Week, the Hult Prize Foundation on September 22 held its Global Final and named the social entrepreneurial startup Banofi Leather from Yale University in New Haven, Connecticut, USA, as the winner of the annual $1 million Hult Prize.

Key Points: 
  • Just days before the start of Paris Fashion Week, the Hult Prize Foundation on September 22 held its Global Final and named the social entrepreneurial startup Banofi Leather from Yale University in New Haven, Connecticut, USA, as the winner of the annual $1 million Hult Prize.
  • The annual Hult Prize competition challenges student entrepreneurs from around the world to create and launch businesses aimed at tackling some of society’s most pressing issues through social entrepreneurship.
  • Every year since 2010, the Hult Prize has posed a different challenge to competitors, with previous contests focused on healthcare, food insecurity, early childhood education, and water access.
  • “The Hult Prize Finals are the culmination of so much hard work by so many student entrepreneurs working to drive social change.

Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma

Retrieved on: 
Friday, September 1, 2023
Swiss Federal Institute of Technology, Swiss, Braunschweig, Scripps Research, Therapy, Biopharmaceutical, Ibete, Anticalin, CSO, Institute of technology, Biotechnology, Hansa, United States Air Force Scientific Advisory Board, Research, Science, Boehringer Ingelheim, Natural science, Executive Committee, Immunoglobulin G, Walter, Biology, Ghassan Hitto, Research fellow, Industrial Affairs Committee (Iceland), Technical University of Braunschweig, Swiss Federal Institute of Aquatic Science and Technology, Fine chemical, Sanofi

LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023.

Key Points: 
  • LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023.
  • Dr. Kaufmann joins Hansa from Pieris Pharmaceuticals where he has served as Chief Scientific Officer since 2019.
  • Søren Tulstrup, President and CEO, Hansa Biopharma said, "We are thrilled to welcome Hitto to Hansa at this pivotal time.
  • Dr. Hitto Kaufmann has served as Chief Scientific Officer at Pieris Pharmaceuticals since 2019.

Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma

Retrieved on: 
Friday, September 1, 2023
Swiss Federal Institute of Technology, Swiss, Braunschweig, Scripps Research, Therapy, Biopharmaceutical, Ibete, Anticalin, CSO, Institute of technology, Biotechnology, Hansa, United States Air Force Scientific Advisory Board, Research, Science, Boehringer Ingelheim, Natural science, Executive Committee, Immunoglobulin G, Walter, Biology, Ghassan Hitto, Research fellow, Industrial Affairs Committee (Iceland), Technical University of Braunschweig, Swiss Federal Institute of Aquatic Science and Technology, Fine chemical, Sanofi

LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023.

Key Points: 
  • LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023.
  • Dr. Kaufmann joins Hansa from Pieris Pharmaceuticals where he has served as Chief Scientific Officer since 2019.
  • Søren Tulstrup, President and CEO, Hansa Biopharma said, "We are thrilled to welcome Hitto to Hansa at this pivotal time.
  • Dr. Hitto Kaufmann has served as Chief Scientific Officer at Pieris Pharmaceuticals since 2019.

The insurability of large-scale cyber risks: The symposium underlines the urgency of sustainably protecting the Swiss economy from major cyber attacks

Retrieved on: 
Monday, June 5, 2023
Helvetia, SME, Insurance, Swiss Federal Institute of Technology, Computer security, ETH, PwC, Politics, ETH Zurich, National Cyber Security Centre (Ireland), Federal, Government, Science, SGV, Werner Salzmann, ICT, SIA, Department of Computer Science of TU Darmstadt, Machine learning, NCSC, Council, Swiss Insurance Association, Swiss Federal Institute of Aquatic Science and Technology, SVP, Computer science, Property insurance, Tourism, Cryptocurrency

The insurability of large-scale cyber risks: The symposium underlines the urgency of sustainably protecting the Swiss economy from major cyber attacks

Key Points: 
  • The insurability of large-scale cyber risks: The symposium underlines the urgency of sustainably protecting the Swiss economy from major cyber attacks
    Helvetia's first cyber symposium tackles the "The challenges of overcoming the main cyber risks".
  • Enhancing cyber resilience through cooperation between business, government and science as a major locational advantage for Switzerland.
  • With cybercrime becoming one of the central top risks, the insurance gap for major cyber events is growing – both nationally and internationally.
  • Helvetia's "The challenges of overcoming the main cyber risks" symposium on 5 June 2023 aggressively brought this acute problem area into the public eye.

ONWARD Announces First-in-Human Use of ARC-IM™ Lead to Restore Movement and Function after Spinal Cord Injury

Retrieved on: 
Monday, May 15, 2023
Blood pressure, Lead, Swiss, IPG, University, University of Calgary, Lausanne, Spinal cord, ARC, Quality of life, Research, CHUV, Movement, Euronext, Patient, EPFL, SCI, FDA, Swiss Federal Institute of Aquatic Science and Technology, Pharmaceutical industry, Medical device, Nature, MD

EINDHOVEN, the Netherlands, May 15, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced the successful first-in-human use of its investigational ARC-IM Lead.

Key Points: 
  • EINDHOVEN, the Netherlands, May 15, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced the successful first-in-human use of its investigational ARC-IM Lead.
  • The ARC-IM Lead delivers targeted electrical pulses to the spinal cord and is a key component of the ONWARD ARC-IM system, an innovative platform engineered to deliver ARC Therapy to address multiple indications.
  • The ARC-IM Lead is designed to be used with the ARC-IM neurostimulator (IPG) and is purpose-built for placement along the spinal cord to stimulate the dorsal roots, with specific parameters designed for each anatomical location.
  • “The purpose-designed ARC-IM Lead will unlock our ability to optimally deliver ARC Therapy to address many of the challenges faced by people with spinal cord injury,” said Dave Marver, CEO of ONWARD.

Nyxoah Appoints Christoph Eigenmann as Chief Commercial Officer

Retrieved on: 
Wednesday, May 10, 2023
Swiss Federal Institute of Technology, Mont-Saint-Guibert, CET, Senior, Obstructive sleep apnea, Marketing, Sales & Marketing Executives International, Biotechnology, Christoph, Christoph Eigenmann, Euronext, Chemical engineering, Patient, Growth, Johnson & Johnson, Neuro, Swiss Federal Institute of Aquatic Science and Technology, Pharmaceutical industry, Swiss

Mont-Saint-Guibert, Belgium – May 10, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Christoph Eigenmann as Chief Commercial Officer.

Key Points: 
  • Mont-Saint-Guibert, Belgium – May 10, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Christoph Eigenmann as Chief Commercial Officer.
  • Christoph will oversee commercial activities globally, be responsible for sales and marketing in existing markets, and new market development.
  • Christoph brings a wealth of experience in medical technologies to Nyxoah.
  • Christoph's years of experience in commercializing medical devices globally will be invaluable as Nyxoah prepares to enter the U.S. market and expands its commercial presence internationally,” commented Olivier Taelman, Nyxoah Chief Executive Officer.

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees 

Retrieved on: 
Wednesday, May 10, 2023
Molecular biology, The Elements of Style, Journal of Thoracic Oncology, Internet Technical Committee, Law, Lung cancer, Oncology, Article, Doctor of Philosophy, European Society for Medical Oncology, Audit committee, Teaching hospital, Professor, Retirement, Journal, University Hospital (Newark, New Jersey), Ageing, Health, Ludwig Cancer Research, Annals of Oncology, Swiss, SIX Swiss Exchange, Teaching, International Association, Research, Attention, Annals, Security (finance), Editor-in-chief, Woman, Swiss Federal Institute of Technology, ESMO, Medicine, NSCLC, US, HKEX, Letter, Swiss Federal Institute of Aquatic Science and Technology, Part, University of Lausanne, Galenica, Strategic Advisory Board for Intellectual Property Policy, HK, Management, Nursing

The Board of HUTCHMED is of the view that Professor Peters will make significant contributions to the Company.

Key Points: 
  • The Board of HUTCHMED is of the view that Professor Peters will make significant contributions to the Company.
  • Mr Simon To, Chairman of HUTCHMED said “On behalf of the Board, I would like to extend a warm welcome to Professor Peters to the Company.
  • Professor Peters is also an independent director of Galenica AG, which is listed on the SIX Swiss Exchange.
  • The director’s fees of Professor Peters as an Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee of the Company under her appointment letter are US$76,000, US$8,000 and US$13,500 per annum respectively.